Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 14 for:    sage | Major Depressive Disorder
Previous Study | Return to List | Next Study

A Study to Evaluate SAGE-217 in Adult Subjects With Major Depressive Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03864614
Recruitment Status : Recruiting
First Posted : March 6, 2019
Last Update Posted : May 13, 2020
Sponsor:
Information provided by (Responsible Party):
Sage Therapeutics

Brief Summary:
This is a phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult subjects with major depressive disorder

Condition or disease Intervention/treatment Phase
Major Depressive Disorder Drug: SAGE-217 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 900 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder
Actual Study Start Date : February 27, 2019
Estimated Primary Completion Date : November 2021
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SAGE-217 Drug: SAGE-217
SAGE-217




Primary Outcome Measures :
  1. Safety and tolerability of the initial treatment with SAGE-217 and re-treatment with SAGE-217, as assessed by the incidence and severity of adverse events. [ Time Frame: 52 Weeks ]
  2. The safety and tolerability of the initial treatment with SAGE-217 and re-treatment with SAGE-217, as assessed by suicidal ideation and behavior using the Columbia Suicide Severity Rating Scale (C-SSRS). [ Time Frame: 52 Weeks ]

Secondary Outcome Measures :
  1. The need for re-treatment with SAGE-217 as assessed by the time to first re-treatment. [ Time Frame: Up to 52 weeks ]
  2. The need for re-treatment with SAGE-217 as assessed by the number of subjects achieving the requirements for re-treatment. [ Time Frame: Up to 52 weeks ]
  3. The need for re-treatment with SAGE-217 as assessed by the number of re-treatment cycles for each subject. [ Time Frame: Up to 52 weeks ]
  4. The response of initial treatment and/or re-treatment as assessed by change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) score. [ Time Frame: Up to 52 weeks ]
  5. The response of initial treatment and/or re-treatment as assessed by percent of subjects achieving HAM-D response at the end of each 14-day treatment period, defined as a ≥50% reduction in HAM-D score from baseline. [ Time Frame: Up to 52 weeks ]
  6. The response of initial treatment and/or re-treatment as assessed by percent of subjects achieving HAM-D remission at the end of each 14-day treatment (initial and/or re-treatment) period, defined as HAM-D total score ≤7. [ Time Frame: Up to 52 weeks ]
  7. The response of initial treatment and/or re-treatment as assessed by percent of subjects achieving Clinical Global Impression - Improvement (CGI-I) score. [ Time Frame: Up to 52 weeks ]
  8. The response of initial treatment and/or re-treatment as assessed by change from baseline in Clinical Global Impression - Severity (CGI-S) score. [ Time Frame: Up to 52 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject has a diagnosis of MDD as diagnosed by SCID-5-CT, with symptoms that have been present for at least a 4-week period.
  2. Subject is in good physical health and has no clinically significant findings, as determined by the Investigator, on physical examination, 12-lead ECG, or clinical laboratory tests.

Exclusion Criteria:

  1. Subject has attempted suicide associated with the current episode of MDD.
  2. Subject has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  3. Subject has had vagus nerve stimulation, electroconvulsive therapy, or has taken ketamine (including esketamine) within the current major depressive episode.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03864614


Contacts
Layout table for location contacts
Contact: Timothy Mariano, MD, PhD, MSc (617) 949-5588 timothy.mariano@sagerx.com

Locations
Hide Hide 74 study locations
Layout table for location information
United States, Alabama
Sage Investigational Site Active, not recruiting
Birmingham, Alabama, United States, 35294
Sage Investigational Site Active, not recruiting
Dothan, Alabama, United States, 36303
United States, Arizona
Sage Investigational Site Active, not recruiting
Phoenix, Arizona, United States, 85012
United States, Arkansas
Sage Investigational Site Active, not recruiting
Little Rock, Arkansas, United States, 72211
United States, California
Sage Investigational Site Active, not recruiting
Anaheim, California, United States, 92805
Sage Investigational Site Active, not recruiting
Cerritos, California, United States, 90703
Sage Investigational Site Recruiting
Costa Mesa, California, United States, 92626
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Culver City, California, United States, 90230
Sage Investigational Site Active, not recruiting
Encino, California, United States, 91316
Sage Investigational Site Recruiting
Irvine, California, United States, 92614
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Los Alamitos, California, United States, 90720
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Newport Beach, California, United States, 92660
Sage Investigational Site Active, not recruiting
Oceanside, California, United States, 92056
Sage Investigational Site Recruiting
Riverside, California, United States, 92503
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
San Marcos, California, United States, 92078
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Santa Ana, California, United States, 92705
Sage Investigational Site Active, not recruiting
Torrance, California, United States, 90502
Sage Investigational Site Active, not recruiting
Upland, California, United States, 91786
United States, Colorado
Sage Investigational Site Recruiting
Colorado Springs, Colorado, United States, 80910
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Denver, Colorado, United States, 80209
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Connecticut
Sage Investigational Site Active, not recruiting
Cromwell, Connecticut, United States, 06416
Sage Investigational Site Active, not recruiting
New Haven, Connecticut, United States, 06511
Sage Investigational Site Recruiting
Norwich, Connecticut, United States, 06360
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Florida
Sage Investigational Site Active, not recruiting
Bradenton, Florida, United States, 34201
Sage Investigational Site Active, not recruiting
Brandon, Florida, United States, 33511
Sage Investigational Site Active, not recruiting
Hialeah, Florida, United States, 33012
Sage Investigational Site Active, not recruiting
Hialeah, Florida, United States, 33015
Sage Investigational Site Active, not recruiting
Lakeland, Florida, United States, 33805
Sage Investigational Site Recruiting
Miami, Florida, United States, 33122
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Miami, Florida, United States, 33125
Sage Investigational Site Active, not recruiting
Miami, Florida, United States, 33134
Sage Investigational Site Active, not recruiting
Miami, Florida, United States, 33175
Sage Investigational Site Active, not recruiting
Pensacola, Florida, United States, 32502
Sage Investigational Site Active, not recruiting
Tampa, Florida, United States, 33634
Sage Investigational Site Active, not recruiting
Winter Park, Florida, United States, 32792
United States, Georgia
Sage Investigational Site Active, not recruiting
Atlanta, Georgia, United States, 30329
Sage Investigational Site Recruiting
Marietta, Georgia, United States, 30060
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Savannah, Georgia, United States, 31405
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Illinois
Sage Investigational Site Active, not recruiting
Chicago, Illinois, United States, 60634
Sage Investigational Site Recruiting
Chicago, Illinois, United States, 60640
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Chicago, Illinois, United States, 60640
United States, Kansas
Sage Investigational Site Active, not recruiting
Prairie Village, Kansas, United States, 66208
Sage Investigational Site Active, not recruiting
Wichita, Kansas, United States, 67214
United States, Kentucky
Sage Investigational Site Active, not recruiting
Louisville, Kentucky, United States, 40202
United States, Louisiana
Sage Investigational Site Recruiting
Lake Charles, Louisiana, United States, 70629
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Shreveport, Louisiana, United States, 71101
United States, Maryland
Sage Investigational Site Active, not recruiting
Baltimore, Maryland, United States, 21287
Sage Investigational Site Active, not recruiting
Towson, Maryland, United States, 21204
United States, Massachusetts
Sage Investigational Site Active, not recruiting
Methuen, Massachusetts, United States, 01844
United States, Missouri
Sage Investigational Site Active, not recruiting
Saint Charles, Missouri, United States, 63304
United States, Nebraska
Sage Investigational Site Recruiting
Lincoln, Nebraska, United States, 68526
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
Omaha, Nebraska, United States, 68134
United States, New Jersey
Sage Investigational Site Recruiting
Cherry Hill, New Jersey, United States, 08002
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Princeton, New Jersey, United States, 08540
Contact       clinicaltrialsinquiry@sagerx.com   
United States, New Mexico
Sage Investigational Site Recruiting
Albuquerque, New Mexico, United States, 87109
Contact       clinicaltrialsinquiry@sagerx.com   
United States, New York
Sage Investigational Site Active, not recruiting
Brooklyn, New York, United States, 11229
Sage Investigational Site Active, not recruiting
Brooklyn, New York, United States, 11235
Sage Investigational Site Active, not recruiting
Glen Oaks, New York, United States, 11004
Sage Investigational Site Active, not recruiting
Mount Kisco, New York, United States, 10549
Sage Investigational Site Active, not recruiting
New York, New York, United States, 10017
Sage Investigational Site Active, not recruiting
New York, New York, United States, 10019
United States, Ohio
Sage Investigational Site Active, not recruiting
Beachwood, Ohio, United States, 44122
United States, Oklahoma
Sage Investigational Site Active, not recruiting
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Sage Investigational Site Recruiting
Salem, Oregon, United States, 97301
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Pennsylvania
Sage Investigational Site Recruiting
Norristown, Pennsylvania, United States, 19403
Contact       clinicaltrialsinquiry@sagerx.com   
United States, Texas
Sage Investigational Site Recruiting
Austin, Texas, United States, 78737
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Austin, Texas, United States, 78759
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Dallas, Texas, United States, 75231
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Recruiting
Houston, Texas, United States, 77081
Contact       clinicaltrialsinquiry@sagerx.com   
Sage Investigational Site Active, not recruiting
San Antonio, Texas, United States, 78229
United States, Vermont
Sage Investigational Site Active, not recruiting
Woodstock, Vermont, United States, 05091
United States, Washington
Sage Investigational Site Active, not recruiting
Bellevue, Washington, United States, 98007
Sage Investigational Site Active, not recruiting
Spokane, Washington, United States, 99202
Puerto Rico
Sage Investigational Site Active, not recruiting
San Juan, Puerto Rico, 00918
Sponsors and Collaborators
Sage Therapeutics
Layout table for additonal information
Responsible Party: Sage Therapeutics
ClinicalTrials.gov Identifier: NCT03864614    
Other Study ID Numbers: 217-MDD-303
First Posted: March 6, 2019    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data sharing will be consistent with the Results submission policy of ClinicalTrials.gov

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depression
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms